- For the six months ended March 31, 2025, Majestic Ideal Holdings Ltd. reported a **net loss of RMB 4,233,119** (US$583,339) on **revenue of RMB 18,230,963** (US$2,512,294), compared to a net income of RMB 237,704 on revenue of RMB 45,724,595 for the same period in 2024.  **[1897532_0001213900-25-093049_ea025734001ex99-1_majestic.htm:1]** 
- As of March 31, 2025, the company had a working capital deficit of **RMB 14,017,887** (US$1,931,715).  **[1897532_0001213900-25-093049_ea025734001ex99-1_majestic.htm:4]** **[1897532_0001213900-25-093049_ea025734001ex99-1_majestic.htm:19]** 
- Subsequent to the reporting period, on July 22, 2025, the company successfully completed its Initial Public Offering, raising **US$15.0 million** in gross proceeds, which is expected to meet working capital and operational funding requirements for at least the next 12 months.  **[1897532_0001213900-25-093049_ea025734001ex99-1_majestic.htm:4]** **[1897532_0001213900-25-093049_ea025734001ex99-1_majestic.htm:20]** 
- The company adopted ASU 2023-07 (Segment Reporting) on October 1, 2024, which **did not have a material impact** on its consolidated financial statements.  **[1897532_0001213900-25-093049_ea025734001ex99-1_majestic.htm:12]**

Ping An Biomedical (MJID)